Midkine and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma: evidence from Mendelian randomization, multi-omics factor analysis, and single-cell transcriptomics

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, in part because its tumor microenvironment actively suppresses antitumor immunity. Midkine (MDK) is a secreted heparin-binding growth factor that is overexpressed in a majority of PDAC tumors, but whether it contributes causally to disease risk and through which cell types it acts have not been firmly established. We combined cis-eQTL Mendelian randomization (GTEx pancreas, n = 328 donors; FinnGen PDAC, 1,252 cases) with multi-omics factor analysis (MOFA) of TCGA-PAAD tumors (n = 149), single-sample gene set enrichment analysis (ssGSEA), cross-species single-cell RNA sequencing, and DepMap CRISPR dependency screening. Mendelian randomization identified MDK as the only gene passing false discovery rate correction for PDAC risk (inverse-variance-weighted odds ratio 1.51, 95% CI 1.19–1.91, p = 6.7 × 10??; FDR = 0.008), with concordant direction across five methods and five independent GWAS. MDK was overexpressed in tumors relative to adjacent normal tissue in an independent cohort (GSE62452, n = 130, p = 5 × 10??), and high expression was associated with shorter overall survival (10.2 versus 21.1 months, p = 0.023). In the MOFA decomposition, MDK localized to a factor characterized by tertiary lymphoid structure gene expression but negative correlation with dendritic cells and macrophages, a pattern consistent with immune exclusion. Single-cell analysis and published functional studies indicated that MDK is produced by cancer-associated fibroblasts and endothelial cells rather than by tumor epithelium, and DepMap data confirmed that MDK is not a cell-autonomous fitness gene. Collectively, these results support a model in which MDK acts through the stromal-immune compartment rather than through tumor cell-intrinsic mechanisms, and raise the possibility that MDK blockade could restore antitumor immunity in PDAC.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766325
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Midkine and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma: evidence from Mendelian randomization, multi-omics factor analysis, and single-cell transcriptomics

Xuejian Chen, zihao Hu, zhencheng Yang, lishan xu
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Pancreatic and Hepatic Oncology Research
preprint

Midkine and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma: evidence from Mendelian randomization, multi-omics factor analysis, and single-cell transcriptomics

Xuejian Chen, zihao Hu, zhencheng Yang, lishan xu
preprint en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, in part because its tumor microenvironment actively suppresses antitumor immunity. Midkine (MDK) is a secreted heparin-binding growth factor that is overexpressed in a majority of PDAC tumors, but whether it contributes causally to disease risk and through which cell types it acts have not been firmly established. We combined cis-eQTL Mendelian randomization (GTEx pancreas, n = 328 donors; FinnGen PDAC, 1,252 cases) with multi-omics factor analysis (MOFA) of TCGA-PAAD tumors (n = 149), single-sample gene set enrichment analysis (ssGSEA), cross-species single-cell RNA sequencing, and DepMap CRISPR dependency screening. Mendelian randomization identified MDK as the only gene passing false discovery rate correction for PDAC risk (inverse-variance-weighted odds ratio 1.51, 95% CI 1.19–1.91, p = 6.7 × 10??; FDR = 0.008), with concordant direction across five methods and five independent GWAS. MDK was overexpressed in tumors relative to adjacent normal tissue in an independent cohort (GSE62452, n = 130, p = 5 × 10??), and high expression was associated with shorter overall survival (10.2 versus 21.1 months, p = 0.023). In the MOFA decomposition, MDK localized to a factor characterized by tertiary lymphoid structure gene expression but negative correlation with dendritic cells and macrophages, a pattern consistent with immune exclusion. Single-cell analysis and published functional studies indicated that MDK is produced by cancer-associated fibroblasts and endothelial cells rather than by tumor epithelium, and DepMap data confirmed that MDK is not a cell-autonomous fitness gene. Collectively, these results support a model in which MDK acts through the stromal-immune compartment rather than through tumor cell-intrinsic mechanisms, and raise the possibility that MDK blockade could restore antitumor immunity in PDAC.

bioRxiv (Cold Spring Harbor Laboratory)
Harbin Medical University (CN)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon